ABUS vs TBPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.
TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.
Compare Another Pair
Related Comparisons
ABUS vs TBPH: Head-to-Head Comparison
This page compares Arbutus Biopharma Corporation (ABUS) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.